| Summary: | The meeting was opened by Prof Atul Deodhar who introduced the prevalence, epidemiology, and clinical features of axial spondyloarthritis (axSpA), and discussed the ongoing unmet needs in the management of axSpA. Prof Dirk Elewaut described the role of the interleukin-17 (IL-17) pathway in the pathogenesis of axSpA. Prof Dominique Baeten reviewed the latest clinical data from existing and emerging therapies for axSpA. Finally, Prof Xenofon Baraliakos discussed recent advances in the assessment of bone inflammation and structural damage in axSpA. Each discussion was followed by questions and answers. The meeting was concluded with an interactive final discussion between the panellists and the audience, with concluding remarks by Prof Atul Deodhar.
|
|---|